<div id="readability-page-1"><div><p>UBS published a research report noting that DAMAI ENT (01060.HK)<span> </span><span> +0.030 (+5.660%)  </span> <span> Short selling $3.72M; Ratio 19.328%  </span>  reported relatively weak results for the fiscal year ended March 2026, mainly due to the company being in an investment cycle and expanding its overseas live entertainment business and IP value chain, which has put short-term profits under pressure.</p><p>UBS expects meaningful contributions from overseas operations to materialize only in 2H of FY2027 or in FY2028, while the core ticketing business remains resilient with strong cash flow. It lowered its earnings forecasts for FY2027 to FY2028 and cut the target price from HKD1.23 to HKD0.78, maintaining a Buy rating. UBS also forecasts DAMAI ENT’s adjusted EBITA margin to remain broadly flat at 10.5% in FY2027, with margins expected to return to a growth trajectory from FY2028 onward as expansion plans scale up and revenue contribution increases. (gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-12 12:25.)</p></div></div>

01060

<p>UBS downgraded DAMAI ENT'starget price to HKD0.78 from HKD1.23, citing weak FY2026 earnings due to overseas expansion costs. While the core ticketing business remains resilient with strong cash flow, UBS expects overseas contributions to materialize in FY2027-2028. The firm maintained a Buy rating, forecasting flat EBITA margins of 10.5% for FY2027 before growth resumes.</p>

UBS: DAMAI ENT Earnings Weak, Cuts TP to HKD0.78